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Abstract
Background: Reliable molecular typing tools are required for a better understanding of the
molecular epidemiology of Plasmodium vivax. The genes msp3a  and  msp1_block5 are highly
polymorphic and have been used as markers in many P. vivax population studies. These markers
were used to assess the genetic diversity of P. vivax strains from French Guiana (South America)
and to develop a molecular typing protocol.
Methods: A total of 120 blood samples from 109 patients (including 10 patients suffered from
more than one malaria episode, samples were collected during each episode) with P. vivax infection
were genotyped. All samples were analysed by msp3a PCR-RFLP and msp1_b5 gene sequencing was
performed on 57 samples. Genotyping protocol applied to distinguish between new infection or
relapse from heterologus hypnozoites and treatment failure or relapse from homologus
hypnozoites was based on analysing first msp3a by PCR-RFLP and secondly, only if the genotypes
of the two samples are identical, on sequencing the msp1_b5 gene.
Results: msp3a alleles of three sizes were amplified by PCR: types A, B and C. Eleven different
genotypes were identified among the 109 samples analysed by msp3a PCR-RFLP. In 13.8% of cases,
a mixed genotype infection was observed. The sequence of msp1_b5 gene revealed 22 unique
genotypes and 12.3% of cases with mixed infection. In the 57 samples analysed by both methods,
45 genotypes were found and 21% were mixed. Among ten patients with two or three malaria
episodes, the protocol allowed to identify five new infections or relapses from heterologous
hypnozoites and six treatment failures of relapses from homologous hypnozoites.
Conclusion: The study showed a high diversity of msp3a and msp1_b5 genetic markers among P.
vivax strains in French Guiana with a low polyclonal infection rate. These results indicated that the
P. vivax genotyping protocol presented has a good discrimination power and can be used in clinical
drug trials or epidemiological studies.
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Background
Malaria remains one of the most serious vector diseases in
the world, and there are between 300 to 500 million cases
of malaria annually. Although considered less dangerous
than Plasmodium falciparum, Plasmodium vivax infections
occasionally cause fatal cases [1-4] and have a large eco-
nomic impact in endemic countries. There are estimated
to be 70–80 million cases of P. vivax infection annually
[5].
French Guiana, an overseas French territory in equatorial
South America, suffers endemic malaria with areas of
moderate and high transmission. The epidemiological
profiles in the two main endemic foci differ. Plasmodium
falciparum is largely predominant along the Maroni River,
western border with Surinam, particularly in "Bush Negro
territory".  Plasmodium vivax is more common in the
Oyapock focus, eastern border with Brazil and in the east-
ern slightly inland areas with a substantial increase since
mild 2001 [6]. Plasmodium malariae is much rarer. The
inland regions of French Guiana, located between the two
Border Rivers, are uninhabited with the exception of two
villages. In coastal regions where three quarters of the
population (205,000 inhabitants according the 2008 offi-
cial censuses) live, occasional bouts of malaria, mainly
imported malaria, are recorded.
Plasmodium vivax is characterized by relapses at various
time intervals associated with the presence of hypno-
zoites. Investigations of relapses of P. vivax infection
report activation of heterologous hypnozoites in East
Timor [7], Thailand and India [8]. There are genetic differ-
ences between the P. vivax populations originating from
these two continents [9,10]. So far, there are few available
data on hypnozoite activation during P. vivax relapse in
patients in South America. Therefore, a better genotypic
characterization of P. vivax at a regional scale is necessary
[11]. To develop reliable epidemiological tools, appropri-
ate genetic markers and practical molecular techniques are
needed. Althought microsatellites are the most highly dis-
criminating markers, their development is laborious and
their analysis costs expensive. Merozoite Surface Proteins
(MSP) have been extensively studied. These proteins of
the erythrocytic stage of the Plasmodium life cycle are
potential targets for vaccine and can also be used for
genetic typing [12]. Pvmsp3a and Pvmsp1 are single copy
genes that are highly polymorphic and currently used for
P. vivax genotyping [13]. The MSP3a protein has a molec-
ular weight of between 148 and 150 KD, and the highly
polymorphic region of the gene encodes an alanine-rich
central domain. Nucleotide polymorphism of msp3a has
been studied by PCR-RFLP in different geographical
regions (Iran and Papua New Guinea [14-17]) and has
also been analysed by gene sequencing in Venezuela and
Thailand [18,19]. Pvmsp1, another well-studied gene
[9,12,20-26], encodes a protein of approximately 1,720
amino acids, and sequence comparisons indicate that the
gene is found as two major sequence types, known as
Belem and Salvador [27]. Interallelic recombination of
these two sequences has been also described [22]. The
Pvmsp1 gene is long, so many genetic studies have focused
on block 5, a polymorphic region suitable for molecular
typing.
The objectives of the present study were firstly to analyse
the genetic polymorphism of Pvmsp3a  and  Pvmsp1_b5
markers in French Guiana; and secondly to propose a pro-
tocol for distinguishing between new infection or relapse
from heterologus hypnozoites and treatment failure or
relapse from homologus hypnozoites. The protocol was
tested with blood samples from patients with multiple
malaria episodes.
Methods
Samples
A total of 120 venous blood samples were collected in
EDTA-tubes during 2005 and 2006 from 109 sympto-
matic malaria patients. Samples were collected as part of
routine diagnosis conducted for 52 patients consulting
the Health Centers at Saint Georges, Camopi and Trois
Sauts living in the malaria Oyapock focus (semi-immune
population) and for 57 patients consulting the Emergency
Service of Cayenne (mainly non immune patients). For
ten patients (R001 to R010) included in the 57, two (and
for R006 three) blood samples were studied.
msp3a RFLP was performed on all samples, the b5 region
of msp1 was sequenced from the patients seen in Cayenne
Hospital. All samples had been sent to the malaria refer-
ence laboratory at Institut Pasteur de la Guyane by health
centres (of St Georges, Camopi and Trois Sauts) and by
the Cayenne Hospital, for expertise and typing as recom-
mended by the health authorities for malaria survey.
Plasmodium vivax treatment was mainly chloroquine
alone, as the use of primaquine was not widely authorized
in 2005 – 2006, on administrative grounds.
DNA extraction
Plasmodium vivax genomic DNA was extracted from 100
μL of EDTA-treated whole blood with DNeasy Blood and
Tissue kits (Qiagen, Hamburg, Germany) following man-
ufacturer's instructions. DNA was eluted in 200 μL of Tris-
EDTA buffer and kept at + 4°C until use or stored at -
20°C.
Genotyping of P. vivax by msp3α PCR-RFLP
Msp3a polymorphism was studied using the PCR-RFLP
method described by Bruce et al [5]. The msp3a gene was
amplified by nested PCR in a final volume of 25 μL; 1 μLMalaria Journal 2009, 8:40 http://www.malariajournal.com/content/8/1/40
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of DNA extract was used for the first PCR, and 1 μL of the
first reaction product was used in the second PCR. Seven
microliters of each second PCR product was digested indi-
vidually with 5 units of HhaI  enzyme (New England
Biolabs Inc, UK) by incubation at 37°C for 3 hours in a
final volume of 20 μL in buffer supplied with the enzyme.
DNA fragments were visualized under UV illumination
after electrophoresis on 1.8% agarose gel (W/V) contain-
ing 0.25 μg/mL of ethidium bromide. Polyclonal infec-
tion can be identified either by observing on
electrophoresis more than one allele of the undigested
PCR product (type A, B or C) or by comparing the sum of
the sizes of digested fragments with the size of the uncut
fragment [7].
Genotyping of P. vivax by msp1_b5 gene sequencing
The DNA fragment encompassing the ICB5-ICB6 region
of the msp1 gene was amplified by PCR as described by
Premawansa et al [15]. Briefly, the amplifications were
performed in 50 μL reaction buffer containing the DNA
template, 1.5 mM MgCl2, 2 μM of each primer ICB5 (5'
CCT ACT ACT TGA TGG TC) and ICB6 (5' CCT TCT GGT
ACA GCT CAA TG), 200 μM of dNTP and 1.5 unit of
AmpliTaq Gold polymerase (Applied Biosystem, Foster
City, CA, USA). The PCR products were visualised by 1%
agarose gel electrophoresis in the presence 0.25 μg/mL of
ethidium bromide. Positive amplifications were purified
using Qiaquick Gel Extaction Kits (Qiagen, Hamburg,
Germany) and analysed by direct double strand sequenc-
ing using BigDye Terminator Kit (Applied Biosystem, Fos-
ter City, CA) with ICB5 and ICB6 primers. Sequences
reactions were performed by the society Millegen (Labege,
France). The amino acid sequences were aligned with the
corresponding Belem and Salvador reference sequences
(GenBank accesion number: M60807 and AF435603
respectively) by using the Clustal W program [28].
Distinction between new infection or relapse from 
heterologous hypnozoites and treatment failure or relapse 
from homogous hypnozoites
Two samples corresponding to sequential of malaria from
a patient are first analysed by PCR-RFLP: i) if the geno-
types found are different, this identifies the second epi-
sode as a new infection or a relapse from heterologous
hypnozoites, and there is no need for further analysis; ii)
if the genotypes are identical, msp1_b5 sequence should
be determined; iii) if samples are of different msp1_b5
type, this identifies the second episode as a new infection
or a relapse from heterologous hypnozoites; iv) if same
genotypes are found, treatment failure or relapse from
homologous hypnozoites can be concluded with a risk of
error proportional to the allele occurrence.
This protocol was assessed for 10 patients, two (or three
for R006) samples were collected during successive
malaria episodes at intervals of 18 days to six months.
Results
Diversity of the Pvmsp3a gene
The Pvmsp3a gene was amplified from total parasite DNA
obtained from 109 patients. PCR products of three
lengths were found: 1.9 kb (type A) corresponding to the
published sequence of the Belem strain, 1.5 kb (type B)
and 1.1 kb (type C). HhaI  digestion indicated that 15
(13.8%) of the 109 blood samples were polyclonal. The
frequencies of the allelic groups in mono-infected sam-
ples (n = 94) were 85.1% for type A, 9.6% for B and 5.3%
for C.
In cases of polyclonal infections, genotype identification
was not possible. The PCR-RFLP patterns of all three gen-
otypes included an approximately 1.0 kb band which was
slightly polymorphic. Consistent with Mueller et al [7],
this band was not used to distinguish patterns because the
size differences were not easily resolved by agarose gel
electrophoresis.  HhaI  digestion revealed nine different
genotypes (A1 to A9) in allelic group A, and only one gen-
otype in each group B and group C (Table 1). Genotypes
A1, A4 and A7 were the most numerous with apparition
frequencies of 27.7, 12.8 and 13.8%, representing 54.3%
of the monoclonal samples; the other six genotypes (A2,
A3, A5, A6, A8 and A9) together made up 30.8% of the
monoclonal infections.
Analysis of Pvmsp1_b5 gene sequence
The msp1_b5 gene was amplified from total parasite DNA
(Table 2). Amplified fragment lengths were between 630
and 720 base pairs. Seven (12.3%) of the 57 samples con-
tained two different msp1_b5 sequences indicating poly-
clonal infection. A total of 22 different sequences were
found, belonging to the three major sequence types:
Table 1: Polymorphism of msp3  gene analysed by PCR-RFLP 
among 109 patient samples.
Allele n (%)
A1 26 (27.7)
A2 6 (6.4)
A3 7 (7.5)
A4 12 (12.8)
A5 7 (7.4)
A6 6 (6.4)
A7 13 (13.8)
A8 2 (2.1)
A9 1 (1.1)
B 9 (9.6)
C 5 (5.3)
Total monoclonal 94 (100)
Polyclonal 15 (13.8)
Total 109
Note: As genotypes of polyclonal samples were not clearly identified, 
they were not be integrated in the frequency calculation.Malaria Journal 2009, 8:40 http://www.malariajournal.com/content/8/1/40
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Belem (five variants, ten samples, 15.6%) Salvador (nine
variants, 21 samples, 32.9%) and a hybrid of these two
sequences (eight variants, 33 samples, 51.6%) [15,19].
The Belem 1 sequence was identical to the Belem M60807
sequence (see Figure 1 and Figure 2), and includes 23 Gln
repetitions. The other Belem genotypes have between 15
to 23 Gln repetitions. The genotypes Belem 2 and 6 have
a substitution of an aspartic acid by a valine in position 57
and the genotype Belem 4 has the same sequence as Sal-
vador 1 between positions 151 and 171. Salvador 1 vari-
ants have similar amino acid sequences differing to
Salvador reference sequence only by point mutations
between positions 59 and 177. Hybrid variant sequences
consist of features from both Salvador and Belem type.
Four of the 22 genotypes identified were found in 51.5%
of the isolates (H1A: 25%, H2B: 12.5%, SAL-1 E: 6.2%
and SAL-1 H: 7.8%) and eighteen (48.5%) with frequen-
cies between 4.7 and 1.7%.
Analysis of samples with the two genotyping methods
Analysis of all the data provided by both genotyping
methods showed 45 different genotypes among 57 ana-
lysed samples, including 12 polyclonal infections (21%)
(Table 3). Twelve of the 57 samples were A1 type; msp1
sequencing of these 12 samples gave four of genotype
H1A, two H2B, two mixed (H1A + H2B and SAL-1 C +
Belem3), one of each H1D, SAL-1 A, SAL-1 H and SAL-1 I.
Among the five A4 samples, msp3a genotyping found four
different msp1 genotypes, two samples being H1A. The six
A7 genotype samples were all different msp1 alleles.
The two genotyping methods did not identify the same
polyclonal infections: there were twelve (21%) such cases,
and msp3a genotyping identified nine (15.8%) and msp1
sequencing seven (12.3%); thus only four patients were
identified as having polyclonal infections by both tech-
niques.
Genotyping of patients with multiple bouts of malaria
For 10 patients, two (or three for R006) samples were col-
lected during successive malaria episodes at intervals of 18
days to six months (Table 4). The patients lived in the lit-
toral zone and were contaminated during a stay along the
Oyapock river. They have received a treatment with chlo-
roquine, which has no effect on the exo-erytrocytic forms.
An another stay in endemic zone, between malaria epi-
sodes, could not be excluded.
Msp3a genotypes of successive samples from patient R001
and R004 were different, indicating that these second epi-
sodes were due to a new infection or a relapse from heter-
Table 2: Polymorphism of msp1_b5 gene sequence among 57 
patients living in non-endemic aera (littoral zone)
Allele n (%) Number of Q repetition
Belem 1 2 (3.1) 23
Belem 2 3 (4.7) 22
Belem 3 1 (1.6) 18
Belem 4 1 (1.6) 17
Belem 5 3 (4.7) 15
H 1A 16 (25.0) 21
H 1B 2 (3.1) 21
H 1C 2 (3.1) 21
H 1D 1 (1.6) 18
H 2A 1 (1.6) 22
H 2B 8 (12.5) 18
H 2C 2 (3.1) 18
H 2D 1 (1.6) 18
SAL-1 A 3 (4.7) NA
SAL-1 B 3 (4.7) NA
SAL-1 C 2 (3.1) NA
SAL-1 D 1 (1.6) NA
SAL-1 E 4 (6.2) NA
SAL-1 F 1 (1.6) NA
SAL-1 G 1 (1.6) NA
SAL-1 H 5 (7.8) NA
SAL-1 I 1 (1.6) NA
Total 64 (100)
Note: NA: Non Applicable
Alignment of amino acid sequences of Pvmsp1_b5 gene for  the 22 distinct allelic forms observed (Belem 1 to SAL-1I),  part 1 of 2 Figure 1
Alignment of amino acid sequences of Pvmsp1_b5 
gene for the 22 distinct allelic forms observed (Belem 
1 to SAL-1I), part 1 of 2. Sequences including the pub-
lished Salvador type sequence (GenBank accession number 
AF435603) were aligned against the sequence Belem type 
(M60807). Drash represent identical residues and stars rep-
resent gaps.Malaria Journal 2009, 8:40 http://www.malariajournal.com/content/8/1/40
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ologous hypnozoites. The first episode of the patient
R002 gave a polyclonal msp3a genotype but the second
was monoclonal; msp1 sequencing revealed different gen-
otypes (SAL-1 H and H2C) in the two samples, and thus
new infection or relapse from heterologous hypnozoites.
For patients R003, R005, R006, R007, R008, R009, and
R010, msp3a genotypes in the first and second samples
were identical. The msp1  sequences from patient R005
samples were not the same (SAL-1 H and SAL-1 E), dem-
onstrating a new infection or a relapse from heterologous
hypnozoites five-and-a-half months after first epidode.
Sequential samples of patients R003, R007, R008, R009
and R010 gave the same msp1 sequences. Genotype occur-
rences of samples from R007, R009 and R010 were infe-
rior to five per cent (SAL-1 B: 4.7%, H1C: 3.1% and
Belem7: 4.7%), therefore, for these patients treatment fail-
ure or relapse from homologous hypnozoites could be
concluded, with a risk of error less that five per cent. This
risk was 7.8 and 6.2% respectively (genotypes found were
SAL-1 H and SAL-1 E) for patients R003 and R008. Patient
R006 suffered three episodes of malaria: the second epi-
sode seems to have been a treatment failure or a relapse
from homologous hypnozoites but with a risk of error of
7.8% (frequency of apparition of SAL-1 H, which was the
genotype found in both first episodes) and the third a new
Alignment of amino acid sequences of Pvmsp1_b5 gene for  the 22 distinct allelic forms observed (Belem 1 to SAL-1I),  part 2 of 2 Figure 2
Alignment of amino acid sequences of Pvmsp1_b5 
gene for the 22 distinct allelic forms observed (Belem 
1 to SAL-1I), part 2 of 2. Sequences including the pub-
lished Salvador type sequence (GenBank accession number 
AF435603) were aligned against the sequence Belem type 
(M60807). Drash represent identical residues and stars rep-
resent gaps.
Table 3: Analysis with Pvmsp3a PCR-RFLP and Pvmsp1_b5 
sequencing of 57 patients living in non-endemic aera (littoral 
zone).
Patient Pvmsp3a allele Pvmsp1_b5 allele
D006 A3 SAL-1 A
D149 A1 H 1D
D209 Mixed genotype H 1A + H 2C
E012 A1 H 1A
E013 B SAL-1 B
E015 A1 H 1A
E016 A4 Belem 2
E017 Mixed genotype SAL-1 C + Belem 2
E021 A5 H 1A
E022 A1 H 2B
E023 A3 SAL-1 A
E029 Mixed genotype H 2C
E030 A2 Belem 1
E037 A7 H 1A
E038 A7 Belem 4
E055 A2 H 2B
E058 Mixed genotype H 2D
E059 Mixed genotype H 1A + H 2B
E065 Mixed genotype H 1A + Belem 5
E090 Mixed genotype SAL-1 D
E096 A3 H 1A
E098 A7 SAL-1 G
E105 A5 H 1C
E119 B H 2B
E132 A6 SAL-1 E
E134 A6 SAL-1 B
E139 A2 SAL-1 E
E141 A1 H 1A + H 2B
E142 A1 SAL-1 C + Belem 2
E153 B H 2B
E161 A2 Belem 5
E162 B H 2B
E170 A1 H 1A
E176 A4 H 1A
E184 A1 H 2B
E186 A4 Belem 1
F004 A1 SAL-1 A
F025 A6 H 1A
F034 A4 H 1A
F036 B H 1B
F042 A6 H 1A
F047 A3 H 1A
F049 A7 SAL-1 E
F058 Mixed genotype H 2A
F060 A7 H 1B + Belem 3
F118 A5 SAL-1 F
F131 A1 H 1A
R 001 A1 SAL-1 H
R 002 Mixed genotype SAL-1 H
R 003 C SAL-1 H
R 004 A1 SAL-1 I
R 005 C SAL-1 H
R 006 C SAL-1 H
R 007 A2 SAL-1 B
R 008 A4 SAL-1 E
R 009 C H 1C
R 010 A7 Belem 5Malaria Journal 2009, 8:40 http://www.malariajournal.com/content/8/1/40
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infection or a relapse from heterologous hypnozoites
(msp1 genotype found: SAL-1 B).
Discussion
Plasmodium vivax diversity has been less extensively stud-
ied than that of P. falciparum. A better characterization of
P. vivax populations in South America was particularly
lacking. A large number of samples must be analysed to
describe the genetic structure of a population, so genetic
markers that are quickly and easily detectable at a reason-
able cost are required. The aims of this work were to study
the polymorphism of msp3a and msp1_b5 markers and to
develop a method for distinguishing between new P. vivax
infections or relapses from heterologous hypnozoites and
treatment failure or relapse from homologous hypno-
zoites. It is of crucial importance clinically when selecting
drug treatment, and in particular chosing between drugs
with or without effect on the exo-erythrocytic stages.
msp3a and msp1 block 5 sequence analysis indicated a
high degree of polymorphism, according to different con-
tinents and countries, making these genes informative for
molecular epidemiological studies. Nevertheless, they
also contain conserved regions allowing amplification of
the nucleotide sequences of interest. The polymorphism
of msp3a can be evaluated rapidly at low cost by PCR-RFLP
[14-17]. Msp1_b5 sequence reveals substantial diversity
[9,12,20-27]. The RFLP technique allows a better discrim-
ination of polyclonal infection samples than sequencing
[29], so this protocol associating RFLP and sequencing
could be used in regions with high rates of polyclonal
infections.
Work on relapses of P. vivax infections demonstrates acti-
vation of heterologous hypnozoites. The genotype of the
acute case is not the same as that of the recurrent infection
in about 71% of relapses observed in Australian soldiers
returning from East Timor [7], 61% of Thai and Burmese
patients and 55% of Indian patients [8].
In French Guiana, 11 different msp3a  genotypes were
identified among 109 samples and 13.8% had mixed-spe-
cies infections. Polyclonal infections were thus less fre-
quent than described by Bruce et al and Cui et al [13,14],
who reported 23% in Papua New Guinea and 19.3% of in
Thailand, respectively. Three previously described types
were found: in 85.1 (type A), 9.6 (type B) and 5.3% (type
C) of the monoclonal samples. The frequencies of these
types reported by Bruce et al were 70.5%, 6.7% and 22.8%
and by Cui et al were 74.8%, 6.5% and 18.7% for A, B and
C, respectively. A Venezuelan study found frequencies of
59.3 for A, 21.9 for B and 18.8% for C [18], and type C has
been reported to be much more frequent in southern Iran
[15] than in the studied population. Over half (54.3%) of
the isolates carried one of only three alleles, A1, A4 and
A7, with the other eight genotypes accounting for the
remaining 45.7% of the monoclonal samples.
Polymorphism was also studied of the msp1_b5-6
sequence. For this protocol, genotyping msp1 is required
in cases for which the msp3a genotype is identical in con-
secutive samples. Twenty-two different sequences in the
57 samples tested were observed. Four genotypes were
strongly represented: H1A, H2B, SAL-1 E and SAL-1 H
made up 51.5% of the alleles and 25% overall were H1A.
The frequencies of the other 18 alleles were between 4.7
and 1.7%. A study in Iran of msp1_b5 sequences in 145
isolates reported 30 genotypes [26]. Seven (12.3%) mixed
infections by msp1 sequencing, and like msp3a polymor-
phism analysis, this suggests that polyclonal infections are
less frequent here than in Papua New Guinea with 38%
[20]. The possible causes for this difference include
malaria endemicity, population and vector density.
From these data a maximal msp1 allelic frequency of 5%,
at which two samples from a same patient found with the
same genotype can be considered to be a treatment failure
or a relapse from homologous hypnozoites. In other
words, relapse should be concluded with a reasonable risk
of error up to 5%. If the genotype found is more repre-
sented, error risk in the conclusion of the analysis will be
proportional to the genotype occurrence found.
The two methods combined revealed 45 genotypes
among the 57 samples and 12 (21%) cases of polyclonal
infection. Only four of these cases of polyclonal infection
were identified as such by both genotyping methods and
eight were identified only by one technique. Five patients
were found by msp3a PCR-RFLP to have polyclonal infec-
tion, but msp1 sequencing suggested mono-infection. In
cases of mixed infection with one genotype being very
poorly represented in the biological sample, sequencing
may not easily detect the minority genotype. In contrast,
msp3a PCR involving nested amplification is more sensi-
tive, and thus an additional allele should be more easily
detected as it will give a 'parasite' band in addition to the
known PCR band or known RFLP pattern. Thus, PCR-
RFLP seems to be more sensitive than direct sequencing
for detecting polyclonal infections [29]. Inversely, three
patients were detected with a polyclonal infection with
msp1 sequencing although msp3  PCR-RFLP detected only
one genotype (two with genotypes A1 and one with A7).
As the frequencies of msp3a genotypes A1 and A7 were
high (27.7 and 13.8%, respectively), it is plausible that the
two msp1 genotypes in these samples have the same msp3a
genotype. The polymorphism of Pvmsp1_b5 and Pvmsp3a
as described in many parts of the world, has been
observed in French Guiana.
Samples from ten patients who had suffered two or three
bouts of malaria (R001 to R010) were analysed. Five epi-
sodes were considered to be new infections or relapse
from heterologous hypnozoites (patients R001, R002,
R004, R005 and third episode for R006). Six of the secondMalaria Journal 2009, 8:40 http://www.malariajournal.com/content/8/1/40
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bouts were identified as being treatment failures or
relapses from homologous hypnozoites. This was con-
cluded for three patients with less than 5% risk of error
and with more than 5% for also three others. The time
interval between episodes for these six patients was 27 to
50 days. Molecular typing methods cannot distinguish
between the both outcomes and treatment failure can
occurs one month after the first episode. Therefore, based
on these data, the question remains open and it is of cru-
cial importance in clinical trials in endemic areas to know
the cause of the latter episode. Moreover, to be sure that
in sequential patient sample genotypes are identical, it
should be verified using more efficient markers, such as
microsatellites.
Conclusion
A high diversity of msp3a and msp1_b5 genetic markers
was observed among P. vivax strains in French Guiana and
revealed a low polyclonal infection rate. The described
protocol associates two molecular techniques for P. vivax
genotyping: msp3a PCR-RFLP, which is a low cost method
based on a highly polymorphic gene, and msp1_b5
sequencing, a highly discriminatory genetic tool, which
provides complementary genotyping data, if required. The
methodology can be easily used as a moderate- or high-
throughput analysis protocol for clinical trials or epidemi-
ological studies.
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